Mari Ariyasu, BPharm

Senior Director
Shionogi & Co., Ltd.

Disclosure: Shionogi & Co., Ltd. (Individual(s) Involved: Self): Employee

Presentation(s):

• 165 - Cefiderocol Treatment for Serious Infections Caused by Carbapenem-resistant Bacteria: Post-hoc Analysis of Outcomes by Pathogen in the CREDIBLE-CR Study

  Oral Abstract